IFN-γ positive selected T-cells

Phase 2Biologic

UUniversity Hospital, Basel, Switzerland

IFN-γ positive selected T-cells is one of 10 biologic programs targeting Hematopoietic Stem Cell Transplantation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematopoietic Stem Cell TransplantationRecruiting

Hematopoietic Stem Cell TransplantationPhase 2

Recruiting

Competition

Competitive Landscape

10 competitors in Hematopoietic Stem Cell Transplantation

#DrugCompanyPhaseTrials

Cyklokapron

JJ Molner

Phase 3

1 2

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 3

Cyclophosphamide IV

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 4

Interleukin 2

EEssen Biotech

Phase 1

1 5

IFN-γ positive selected T-cells

UUniversity Hospital, Basel, Switzerland

Phase 2

1 6

Dose Extension

IInstitute of Hematology & Blood Diseases Hospital, China

Phase 1

1 7

Piperacillin-Tazobactam Combination Product

TThe University of Queensland

Preclinical

1 8

Haecs

TThe Second Affiliated Hospital of Chongqing Medical University

Preclinical

1 9

Hematopoietic Stem Cell

TTalaris Therapeutics Inc.

Preclinical

2 10

Baracle Tab.

SSeoul St. Mary's Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Hematopoietic Stem Cell Transplantation

NCT02007356

Clinical

Trials by Indication[1]

Hematopoietic Stem Cell Transplantation1 trial

A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT02007356·30 enrolled

Cytomegalovirus (CMV) Infection1 trial

Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection

Withdrawn·YYae-Jean Kim·Phase 1/2·NCT02346617

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for IFN-γ positive selected T-cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IFN-γ positive selected T-cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IFN-γ positive selected T-cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Basel, Switzerland company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversity Hospital, Basel, Switzerland

IFN-γ positive selected T-cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Hematopoietic Stem Cell Transplantation1 trial

Cytomegalovirus (CMV) Infection1 trial

References

Drug Info

Quick Facts

Related News